KARYOPHARM THERAPE revenue breakdown overview

KARYOPHARM THERAPE revenue for the last year amounted to 122.95 M CHF, the most of which — 122.95 M CHF — came from its highest performing source at the moment, Drugs, the year earlier bringing 145.25 M CHF. The greatest contribution to the revenue figure was made by United States — last year it brought KARYOPHARM THERAPE 122.95 M CHF, and the year before that — 145.25 M CHF.